Hal Mintz, Sabby Management Report 7.43% Stake in Oxygen Biotherapeutics, Inc. (OXBT)

Hal Mintz‘ Sabby Management has reported a new stake in the biotechnology company Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), a new filing with the SEC shows. Sabby currently owns over 1.96 million shares of the company, equal to 7.43% of the outstanding stock. The value of the passive position amounts to around $11.61 million, at the current price of the company’s stock.

Oxygen Biotherapeutics

Interestingly, Sabby Management purchased the shares of Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT), after disclosing in its latest 13F filing, dumping the holding, which previously contained some 36,700 shares. Out of the funds that we track, Ellington, led by Mike Vranos, is the only one that disclosed holding Oxygen Biotherapeutics in its equity portfolio as at the end of last year. Ellington’s stake amasses 34,200 shares, with a reported value of $154,000.

Sabby’s latest acquisition falls in line with the recently announced public offering launched by Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT). The company intends to sell around $52 million worth of stock, for a price of $5.60 per share, Oxygen Biotherapeutics said in a statement. The proceeds will be used for company’s clinical trials as well as for obtaining regulatory approvals for two of its drugs: Levosimendan and Oxycyte. In addition the company will also spend the cash it receives from the proceeds to support the manufacturing of the aforementioned drugs and for development of other product candidates, the statement added.

Moreover, at the beginning of March, Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) announced that its Oxycyte drug has been reviewed by U.S. FDA agency, which decided to lift the clinical hold of the drug, which means a green light for the clinical development of the product in the U.S, another press release said.

On the back of positive news related to the development of the company, the stock of Oxygen Biotherapeutics has been gaining ground since the beginning of the year, and is already 30% year-to-date.

Recently, Sabby Management disclosed adding other two Healthcare stocks to its equity portfolio. The fund disclosed ownership of 437,500 shares of Recro Pharma Inc (NASDAQ:REPH) and 1.7 million shares of Bioline RX Ltd (NASDAQ:BLRX), both stakes amassing around 5% of the companies’.

Disclosure: none

Recommended Reading:

RA Capital Discloses New Passive Stake in Repros Therapeutics Inc (RPRX)

Steven Cohen Ups His Bets on NQ Mobile Inc (ADR) (NQ)

Himanshu H. Shah Ups Stake in Corinthian Colleges Inc (COCO); Sends Letter to the Board

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

The 10 Most Peaceful Countries in the World

5 Big Reasons Communism Failed

The 15 Most Famous Carl Icahn Quotes

10 Scary Animals that are Actually Harmless

The 8 Most Famous Singer-Actors in Entertainment

The 10 Longest Wars of All Time

The 13 Worst Looking Foods that Taste Great

The 6 Most Gruesome Injuries Suffered During a Sports Match

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!